This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Lordick F, Ehlken B, Ihbe-Heffinger A, Berger K, Krobot KJ, Pellissier J, Davies G, Deuson R.Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. European Journal of Cancer 43: 299-307, No. 2, Jan 2007
Rights and permissions
About this article
Cite this article
Aprepitant good value for money for preventing CINV. Pharmacoecon. Outcomes News 524, 5 (2007). https://doi.org/10.2165/00151234-200705240-00009
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705240-00009